TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Innate Pharma SA ( (FR:IPH) ) has provided an update.
On November 28, 2025, Innate Pharma S.A. released its total number of shares and voting rights as of November 27, 2025, in compliance with French regulatory requirements. The company reported 92,196,523 ordinary shares and a total of 92,962,943 theoretical voting rights. This announcement ensures market transparency and informs stakeholders about the company’s shareholding structure, potentially impacting investor decisions and market perception.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR1.50 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its expertise in antibody-engineering and innovative target identification to create next-generation antibody therapeutics. Innate Pharma’s portfolio includes potential first and/or best-in-class assets targeting areas of high unmet medical need, such as IPH4502, lacutamab, and monalizumab. The company collaborates with major biopharmaceutical firms like Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD. Innate Pharma is listed on Euronext Paris and Nasdaq.
Average Trading Volume: 277,103
Technical Sentiment Signal: Strong Sell
Current Market Cap: €153.4M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.